Xanax and allergy medication are sometimes taken together, but this combination carries important safety considerations that patients and carers should understand. Xanax (alprazolam) is a benzodiazepine that calms the central nervous system, whilst many allergy medicines — particularly older, sedating antihistamines — share similar depressant effects. When combined, these medicines can amplify sedation, impair coordination, and in serious cases cause respiratory depression. This article explains how alprazolam and allergy treatments interact, which medicines pose the greatest risk, what warning signs to watch for, and how UK guidance from the NHS, NICE, and MHRA can help you make safer treatment choices.

How Alprazolam (Xanax) and Allergy Medications Affect the Body

Alprazolam enhances GABA activity to produce CNS sedation, whilst first-generation antihistamines also cross the blood-brain barrier; the main interaction concern is additive CNS depression rather than pharmacokinetic interference.

Alprazolam (sold under the brand name Xanax) is a benzodiazepine medicine prescribed for anxiety disorders and panic attacks. It works by enhancing the effect of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the brain. By increasing GABA activity, alprazolam produces a calming, sedative effect on the central nervous system (CNS), reducing feelings of anxiety and tension. In the UK, alprazolam is a Class C controlled drug under the Misuse of Drugs Act 1971 and is listed under Schedule 4 Part I of the Misuse of Drugs Regulations 2001. It is not commonly prescribed in NHS settings, where clinicians tend to favour other anxiolytics or psychological therapies in line with NICE guidance (CG113).

Allergy medications cover a broad range of treatments. The most widely used are antihistamines, which block histamine H1 receptors to relieve symptoms such as sneezing, itching, and a runny nose. These are divided into two main categories:

• First-generation (sedating) antihistamines (e.g., chlorphenamine, promethazine) — these cross the blood-brain barrier and have notable sedative properties.

• Second-generation (non-sedating) antihistamines (e.g., cetirizine, loratadine, fexofenadine) — these are less likely to cause sedation as they have limited CNS penetration, though some individuals may still experience drowsiness.

Other allergy treatments include intranasal corticosteroid sprays (e.g., fluticasone, beclometasone), leukotriene receptor antagonists (e.g., montelukast), and immunotherapy. Intranasal corticosteroids act locally within the nasal passages with negligible systemic absorption and have no meaningful CNS interaction with alprazolam.

When considering the combined use of alprazolam with any allergy medicine, the principal concern is pharmacodynamic: overlapping CNS depressant effects — particularly additive sedation — rather than metabolic or pharmacokinetic interactions, which are generally minimal for typical allergy medicines.

Risks of Taking Alprazolam Alongside Antihistamines or Allergy Treatments

Combining alprazolam with sedating antihistamines can cause additive CNS depression, leading to excessive drowsiness, impaired coordination, cognitive impairment, and potentially dangerous respiratory depression — particularly in older adults or those with respiratory conditions.

Not sure if this is normal? Chat with one of our pharmacists →

The primary concern when combining alprazolam with allergy medications — particularly sedating antihistamines — is additive CNS depression. Both alprazolam and first-generation antihistamines suppress central nervous system activity, and taking them together can amplify sedation to a potentially dangerous degree. This combination may result in excessive drowsiness, impaired coordination, slowed reaction times, and, in severe cases, respiratory depression.

Respiratory depression is of particular concern in vulnerable individuals, including older adults, those with pre-existing respiratory conditions such as chronic obstructive pulmonary disease (COPD) or obstructive sleep apnoea, and those who consume alcohol. The risk is further increased if other CNS depressants are also being taken, such as opioid analgesics, sedative antidepressants, or gabapentinoids. Patients should avoid alcohol and these other CNS-active medicines whilst taking alprazolam alongside any sedating allergy treatment. UK SmPCs for alprazolam, chlorphenamine, and promethazine all include warnings about additive CNS depression when these medicines are combined.

Beyond sedation, there are additional risks to consider:

• Cognitive impairment: Memory, concentration, and decision-making may be significantly affected.

• Falls and accidents: Particularly relevant for older patients, where the risk of falls and fractures is already elevated.

• Dependence: Prolonged use of alprazolam carries a risk of physical dependence; patients should not adjust their dose or stop taking it without medical guidance.

• Driving and operating machinery: The combination is likely to render a person unfit to drive. Under UK law, it is an offence to drive whilst impaired by drugs, including prescribed medicines. Further information is available at GOV.UK: Drugs and driving — the law.

Even second-generation antihistamines, though generally considered non-sedating, may contribute to CNS effects in some individuals, particularly at higher doses or in those who are sensitive to such medicines. Caution is therefore warranted across all antihistamine classes when used alongside alprazolam.

Which Allergy Medications Are Most Likely to Interact With Alprazolam

First-generation antihistamines — chlorphenamine, promethazine, and hydroxyzine — carry the highest interaction risk; intranasal corticosteroids are low-risk, whilst second-generation antihistamines such as fexofenadine pose the least CNS concern.

Not all allergy medications carry the same level of interaction risk with alprazolam. The degree of concern largely depends on the medicine's CNS activity — specifically, its potential to cause additive sedation.

First-generation (sedating) antihistamines pose the highest risk of interaction. These include:

• Chlorphenamine — widely available over the counter and commonly used for hay fever, urticaria, and allergic reactions. Its strong sedative properties make it particularly hazardous in combination with alprazolam.

• Promethazine — used for allergies and as a short-term sleep aid; it has pronounced CNS depressant effects and should not be combined with benzodiazepines without medical supervision.

• Hydroxyzine — sometimes prescribed for both allergy and anxiety. Combining it with alprazolam significantly increases sedation risk. Importantly, the MHRA issued a Drug Safety Update in 2015 highlighting hydroxyzine's risk of QT interval prolongation; dose restrictions apply (maximum 100 mg daily in adults), and it should be used with caution in older patients and those with cardiac risk factors.

Second-generation (non-sedating) antihistamines such as cetirizine, loratadine, and fexofenadine carry a lower but not negligible risk. Cetirizine, in particular, can cause drowsiness in some patients and may have a mild additive effect when taken with alprazolam. Fexofenadine has minimal CNS penetration and is generally considered the least sedating option in this class.

Regarding other allergy treatments, montelukast (a leukotriene receptor antagonist) has been associated with neuropsychiatric side effects including anxiety, depression, sleep disturbances, and suicidal thoughts. The MHRA issued a Drug Safety Update in 2019 strengthening warnings about these neuropsychiatric risks. Patients taking montelukast alongside alprazolam should be monitored for any new or worsening mood or behavioural changes, and any concerns should be reported promptly to a GP.

Experiencing these side effects? Our pharmacists can help you navigate them →

Intranasal corticosteroid sprays such as fluticasone or beclometasone are generally considered low-risk; they act locally with negligible systemic absorption and carry no meaningful CNS interaction risk with alprazolam.

Always consult a pharmacist or GP before combining any allergy treatment with a controlled medicine such as alprazolam. The BNF and UK SmPCs (available via the Electronic Medicines Compendium, emc) provide authoritative interaction information for individual medicines.

Signs of a Harmful Interaction and When to Seek Medical Advice

Serious signs such as slow or laboured breathing, extreme sedation, or cyanosis require an immediate 999 call; unexpected drowsiness or confusion should prompt contact with a GP or NHS 111.

Recognising the signs of a harmful drug interaction early is essential for patient safety. When alprazolam is taken alongside sedating allergy medications, the effects can develop quickly — sometimes within an hour of taking both medicines. Patients and carers should be aware of the following warning signs:

Mild to moderate symptoms:

• Unusual or excessive drowsiness

• Difficulty concentrating or confusion

• Slurred speech

• Loss of coordination or unsteady gait

• Blurred vision

• Nausea or dizziness

Serious symptoms requiring urgent medical attention:

• Slow, shallow, or laboured breathing

• Extreme sedation or inability to be roused

• Loss of consciousness

• Bluish tinge to the lips or fingertips (cyanosis)

• Severe confusion or disorientation

If any serious symptoms occur, call 999 immediately or go to the nearest Accident and Emergency (A&E) department. Do not wait to see if symptoms resolve on their own, as respiratory depression can deteriorate rapidly.

For milder concerns — such as unexpected drowsiness or confusion after starting a new allergy medicine — patients should contact their GP or call NHS 111 for advice. It is also advisable to speak to a community pharmacist before purchasing any over-the-counter allergy remedy if you are currently prescribed alprazolam or any other benzodiazepine. Pharmacists are well-placed to identify potential interactions and suggest safer alternatives.

If you or a healthcare professional suspects a side effect or interaction involving these medicines, please report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. This helps the MHRA monitor the safety of medicines in the UK. Always carry an up-to-date list of your current medicines to share with healthcare professionals.

Safer Alternatives for Managing Allergies With Anxiety Medication

Fexofenadine and intranasal corticosteroids are the preferred allergy treatment options for patients on alprazolam, as both carry minimal CNS interaction risk; NICE CKS recommends intranasal corticosteroids as first-line for moderate-to-severe allergic rhinitis.

For individuals taking alprazolam or other benzodiazepines, selecting the right allergy treatment requires careful consideration. The goal is to manage allergy symptoms effectively whilst minimising the risk of CNS-related adverse effects.

Preferred antihistamine options for those on anxiolytics include:

• Fexofenadine — considered one of the least sedating antihistamines available, with minimal CNS penetration, making it a generally safer choice. Note that it is available over the counter only for certain strengths and indications; check with a pharmacist regarding appropriate use.

• Loratadine — another non-sedating option widely available over the counter, though individual responses can vary and some people may still experience drowsiness.

• Intranasal corticosteroids (e.g., fluticasone nasal spray, beclometasone nasal spray) — these act locally in the nasal passages with minimal systemic absorption and carry no meaningful CNS interaction risk. NICE CKS guidance on allergic rhinitis recommends intranasal corticosteroids as a first-line treatment for moderate-to-severe allergic rhinitis.

For eye-related allergy symptoms, topical antihistamine eye drops (e.g., azelastine or olopatadine) offer localised relief with negligible systemic absorption.

It is important to note that even antihistamines labelled as 'non-drowsy' can still cause drowsiness in some individuals. Patients should assess their own response before driving or operating machinery.

From an anxiety management perspective, NICE guidelines (CG113) and the associated Quality Standard (QS53) recommend psychological therapies — particularly cognitive behavioural therapy (CBT) — as a first-line treatment for generalised anxiety disorder and panic disorder. Reducing reliance on benzodiazepines through structured psychological support may, in turn, reduce the complexity of managing concurrent allergy treatment.

Patients should always discuss any changes to their allergy management with their GP or specialist, particularly if they are on long-term alprazolam. A structured medication review can help identify the safest combination of treatments tailored to the individual's clinical needs and risk profile.

Guidance From the NHS and MHRA on Combining These Medicines

The MHRA and NHS advise caution when combining benzodiazepines with CNS-active allergy medicines; NICE CG113 discourages long-term benzodiazepine use, and suspected interactions should be reported via the MHRA Yellow Card Scheme.

Both the NHS and the Medicines and Healthcare products Regulatory Agency (MHRA) provide important guidance relevant to the combined use of benzodiazepines and CNS-active allergy medications. Whilst there is no single dedicated guideline addressing alprazolam and antihistamines specifically, UK regulatory and clinical frameworks offer clear direction.

The MHRA has consistently highlighted the risks of combining benzodiazepines with other CNS depressants, including sedating antihistamines. UK SmPCs (available via the Electronic Medicines Compendium, emc) and the BNF include interaction warnings advising caution with such combinations, particularly in older adults and those with respiratory conditions. The MHRA has also issued specific Drug Safety Updates relevant to allergy medicines used alongside CNS depressants — notably the 2015 update on hydroxyzine (QT prolongation and dose restrictions) and the 2019 update on montelukast (neuropsychiatric reactions).

The MHRA Yellow Card Scheme enables patients and healthcare professionals to report suspected adverse drug reactions, including those arising from drug interactions. Reports can be submitted at yellowcard.mhra.gov.uk or via the Yellow Card app. This remains an important tool for ongoing pharmacovigilance in the UK.

NICE guidance on anxiety disorders (CG113) recommends that benzodiazepines should not be used routinely for long-term anxiety management due to risks of dependence and adverse effects. This guidance supports minimising polypharmacy involving CNS-active agents.

From an NHS perspective, patients are encouraged to:

• Always inform their GP or pharmacist of all medicines they are taking, including over-the-counter and herbal remedies.

• Ask about the New Medicine Service (NMS) or Discharge Medicines Service if starting a new medicine, or request a Structured Medication Review (SMR) through their GP practice if they are on multiple long-term medicines.

• Use the NHS 111 service for non-emergency medication queries.

• Refer to GOV.UK: Drugs and driving — the law for guidance on the legal implications of driving whilst taking CNS-depressant medicines.

In summary, whilst there is no absolute contraindication in all cases, combining alprazolam with sedating allergy medications warrants careful clinical oversight and should not be undertaken without professional advice.

Frequently Asked Questions